Several mechanisms have been proposed to explain the effect of estrogen administration on cardiac hypertrophy such as the mitigation of Ang-II signaling [33] and increased degradation of calcineurin as hypertrophic factor [34]. The gene discussed is AGT; the disease is cardiac hypertrophy.